Loading clinical trials...

The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma | Clinical Trials | Clareo Health

UNKNOWN

The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma

A Prospective Study of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma

NCT04489264•Peking University

View on ClinicalTrials.gov

Summary

The role of autologous stem cell transplantation (ASCT) in the first remission (CR1 \& PR1) of peripheral T-cell lymphomas (PTCLs) is not well defined. This study analyzed the impact of ASCT on the clinical outcomes of patients with newly diagnosed PTCL in CR1 and PR1.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with confirmed pathological diagnosis of aggressive PTCL
•Age 18-65 years old
•Achieving CR or PR after first-line therapy

Exclusion Criteria

•Subtypes with a more indolent course, including precursor T/natural killer neoplasms, T-cell large granular lymphocytic leukemia, mycosis fungoides other than transformed mycosis fungoides, Sézary syndrome, and primary cutaneous CD30-positive disorders.

Locations (1)

Beijing Cancer Hospital

Beijing, China

Key Dates

Start Date

November 30, 2020

Primary Completion Date

November 30, 2023

Completion Date

November 30, 2025

Last Updated

December 4, 2020

Enrollment

ESTIMATED participants

Conditions

Peripheral T Cell Lymphoma

Interventions

Transplant, Autologous

DRUG

Contacts

Jun Zhu, Dr.

CONTACT

+86-13910333346 zhu-jun2017@outlook.com

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

NCT07389616

Peripheral T Cell Lymphoma

View study

RECRUITINGPHASE2

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

NCT07356245

T-cell LymphomaGraft Versus Host Disease+6 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 4, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma

Inclusion Criteria

Exclusion Criteria

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma